kabutan

CHUGAI PHARMACEUTICAL CO., LTD.(4519) Summary

4519
TSE Prime
CHUGAI PHARMACEUTICAL CO., LTD.
7,381
JPY
+40
(+0.54%)
Jul 28, 1:03 pm JST
49.99
USD
Jul 28, 12:04 am EDT
Result
PTS
outside of trading hours
7,380.1
Jul 28, 1:04 pm JST
Summary Chart Historical News Financial Result
PER
PBR
6.12
Yield
3.39%
Margin Trading Ratio
5.77
Stock Price
Jul 28, 2025
Opening Jul 28, 9:00 am
7,340 JPY 49.66 USD
Previous Close Jul 25
7,341 JPY 49.95 USD
High Jul 28, 9:17 am
7,457 JPY 50.48 USD
Low Jul 28, 9:06 am
7,277 JPY 49.26 USD
Volume
1,115,400
Trading Value
8.23B JPY 0.06B USD
VWAP
7376.23 JPY 49.96 USD
Minimum Trading Value
738,100 JPY 4,999 USD
Market Cap
12.39T JPY 0.08T USD
Number of Trades
4,940
Liquidity & Number of Trades
As of Jul 28, 2025
Liquidity
High
1-Year Average
6,429
1-Year High Apr 18, 2025
34,079
Margin Trading
Date Short Interest Long Margin Positions Ratio
Jul 18, 2025 82,500 810,000 9.82
Jul 11, 2025 77,000 840,100 10.91
Jul 4, 2025 85,300 724,100 8.49
Jun 27, 2025 85,900 469,900 5.47
Jun 20, 2025 85,800 684,200 7.97
Company Profile
CHUGAI PHARMACEUTICAL CO., LTD. is a major pharmaceutical company. As a subsidiary of Roche, it has expanded its product line, including Tamiflu. The company's main focus is on anticancer drugs and rheumatoid arthritis treatments.
Sector
Pharmaceuticals
CHUGAI PHARMACEUTICAL CO., LTD. is a pharmaceutical company specializing in the research, development, manufacturing, and sales of pharmaceuticals, operating under the Swiss pharmaceutical giant Roche. In Japan, the company sells its own products through authorized dealers, while overseas it has sales bases in Europe, Taiwan, China, and other regions. Manufacturing is carried out at the company's domestic and international factories, as well as through contracted partners. As a member of the Roche Group, Chugai purchases some raw materials from Roche and distributes some products internationally through Roche's network. The company focuses on developing innovative drugs, particularly in the fields of cancer treatment and rheumatoid arthritis, while pursuing global business expansion.